CeriBell (NASDAQ:CBLL – Get Free Report) is anticipated to post its quarterly earnings results after the market closes on Tuesday, February 25th. Analysts expect CeriBell to post earnings of ($0.32) per share and revenue of $17.55 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.
CeriBell Stock Up 6.8 %
CeriBell stock opened at $24.69 on Monday. The firm’s 50-day moving average price is $23.53. CeriBell has a 52-week low of $18.69 and a 52-week high of $32.75.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on CBLL. William Blair began coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “outperform” rating for the company. Bank of America began coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price objective for the company. TD Cowen increased their price objective on shares of CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a report on Monday, December 9th. Canaccord Genuity Group began coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, JPMorgan Chase & Co. initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $32.60.
About CeriBell
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Read More
- Five stocks we like better than CeriBell
- EV Stocks and How to Profit from Them
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- How to Calculate Options Profits
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- How to Invest in Biotech Stocks
- These 5 Energy Stocks Hedge Inflation With Growth Potential
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
